KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to 0.26%.

  • Acadia Pharmaceuticals' Return on Capital Employed rose 700.0% to 0.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.26%, marking a year-over-year increase of 700.0%. This contributed to the annual value of 0.4% for FY2024, which is 5800.0% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Return on Capital Employed stood at 0.26% for Q3 2025, which was up 700.0% from 0.28% recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Return on Capital Employed peaked at 0.34% during Q4 2024, and registered a low of 0.48% during Q4 2022.
  • For the 5-year period, Acadia Pharmaceuticals' Return on Capital Employed averaged around 0.16%, with its median value being 0.28% (2021).
  • Its Return on Capital Employed has fluctuated over the past 5 years, first plummeted by -2000bps in 2022, then surged by 5500bps in 2024.
  • Acadia Pharmaceuticals' Return on Capital Employed (Quarter) stood at 0.28% in 2021, then crashed by -71bps to 0.48% in 2022, then surged by 65bps to 0.17% in 2023, then surged by 300bps to 0.34% in 2024, then decreased by -22bps to 0.26% in 2025.
  • Its Return on Capital Employed stands at 0.26% for Q3 2025, versus 0.28% for Q2 2025 and 0.27% for Q1 2025.